Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors

Abstract

Objectives: To define the incidence and severity of ovarian hyperstimulation syndrome (OHSS) occurring in oocyte donors. Methods: Women ( n = 149) aged 31.3 ± 4.8 years (mean ± S.D., range 21–41 years) participated as designated oocyte donors and underwent 400 consecutive cycles of controlled ovarian stimulation using human menopausal gonadotropin following pituitary downregulation with gonadotropin-releasing agonist. Patients were monitored by serial transvaginal ultrasound examinations and serum estradiol (E 2) determinations. Oocytes (15.6 ± 7.5 per aspiration; range 2–57) were harvested by ultrasound-directed transvaginal follicle aspiration 36 h following the intramuscular injection of human chorionic gonadotropin (hCG). Follow-up examination occurred 1 and 2 weeks post-aspiration. Results: On the day of hCG injection E 2 levels ranged from 512 to 13 502 pg/ml (mean 2902.7 ± 1486.9 pg/ml). Over the next few weeks the degree of hyperstimulation in donors was staged: mild 65% (grade I, n = 98; grade II, n = 162); moderate 33.5% (grade III, n = 120; grade IV, n = 14); severe 1.5% (grade V, n = 6; grade VI, n = 0). Associated preaspiration E 2 levels were: grade I, 1120 ± 424 pg/ml; grade II, 2084 ± 613 pg/ml; grade III, 3785 ± 1713 pg/ml; grade IV, 5370 ± 1264 pg/ml; grade V, 4286 ± 1100 pg/ml. Worsening OHSS was associated with increasing levels of E 2. There were no serious complications and hospitalization was not required. All symptoms resolved within 30 days of aspiration, disappearing by the time of the first menstrual flow in women of grade-III or lower stage. Conclusion: Although oocyte donors commonly experienced exaggerated levels of serum E 2 they rarely (<2%) developed severe OHSS. This may be attributable to their lack of embryo transfer which avoids exacerbating the illness.